Results 101 to 110 of about 6,251,767 (305)

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte   +10 more
wiley   +1 more source

Enter all Data on the Create New Record page................................................................................2 [PDF]

open access: yes
WISPER facilitates the process of routing applications and agreements for extramural support by capturing the necessary data up to and tracking through the generation of the award.
Principal Investigators Ceas   +1 more
core  

Artificial Intelligence for Digital Heritage Innovation: Setting up a R&D Agenda for Europe

open access: yesHeritage
Artificial intelligence (AI) is a game changer in many fields, including cultural heritage. It supports the planning and preservation of heritage sites and cities, enables the creation of virtual experiences to enrich cultural tourism and engagement ...
Sander Münster   +7 more
doaj   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

open access: yesMolecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop   +10 more
wiley   +1 more source

CBERN - The First Six Years: Challenges and Achievements [PDF]

open access: yes, 2012
CBERN was created in 2006. Its mandate was to create a network able to address critically, persuasively and visibly the foundational role of ethics in business and economic development. The task facing the network was significant. The field was fractured
Canadian Business Ethics Research Network (CBERN)
core  

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

open access: yesMolecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche   +8 more
wiley   +1 more source

An overview and single-arm meta-analysis of immune-mediated adverse events following COVID-19 vaccination

open access: yesFrontiers in Pharmacology
BackgroundWe conducted an overview to assess immune adverse effects associated with the COVID-19 vaccine, guiding safer choices and providing evidence-based information to clinicians.MethodsForty-three studies on adverse effects of vaccines were reviewed
Donghua Yang   +5 more
doaj   +1 more source

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing

open access: yesMolecular Oncology, EarlyView.
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy